| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 02/12/2009 | WO2008113770A3 Anti-androgen peptides and uses thereof in cancer therapy |
| 02/12/2009 | WO2008076158A3 Nontoxic ricin mutant compositions and methods |
| 02/12/2009 | WO2008028963A3 Calreticulin for its use as a medication for the treatment of cancer in a mammal |
| 02/12/2009 | WO2007014743A8 Cd33-specific single-chain immunotoxin and method of use |
| 02/12/2009 | US20090043280 Vaccine Delivery Service |
| 02/12/2009 | US20090043077 Conjugation of streptococcal capsular saccharides |
| 02/12/2009 | US20090043076 Modified interferon beta with reduced immunogenicity |
| 02/12/2009 | US20090042797 Gamma-heregulin |
| 02/12/2009 | US20090042796 Derivatives of the il-2 receptor gamma chain, their production and use |
| 02/12/2009 | US20090042794 Group b streptococcus antigens and corresponding dna fragments |
| 02/12/2009 | US20090042230 Flea allantoinase proteins and uses thereof |
| 02/12/2009 | US20090041852 Dry powder compositions and systems for poultry vaccination |
| 02/12/2009 | US20090041836 Glycolipopeptide and uses thereof |
| 02/12/2009 | US20090041834 Compositions and methods for treating lymphoma |
| 02/12/2009 | US20090041810 Immunostimulating polyphosphazene compounds for intradermal immunization |
| 02/12/2009 | US20090041808 Detection/Measurement Of Malaria Infection Disease Utilizing Natural Immunity By Hemozoin Induction, Screening Of Preventative Or Therapeutic Medicine For Malaria Infection Disease, And Regulation Of Natural Immunity Induction |
| 02/12/2009 | US20090041807 preventing aggregation of outer membrane vesicles of bacteria; measuring by adjusting zeta potential; use in vaccination |
| 02/12/2009 | US20090041806 Use of prodrugs of gaba analogs, antispasticity agents, and prodrugs of gaba b receptor agonists for treating spasticity |
| 02/12/2009 | US20090041805 Locally administering botulinum toxin powder to a patient using a using a needleless syringe connected to a tank of compressed inert gas, such as helium, for producing a supersonic gas flow; gold, platinum, tungsten or ice crystal carrier; pain is alleviated within 1 to 7 days of administration |
| 02/12/2009 | US20090041804 Foreign nucleic acid molecule encoding multiple costimulatory molecules, such as B7-1 or B7-2 (antigens), intercellular adhesion molecules and leukocyte function associated antigen-3 |
| 02/12/2009 | US20090041803 Dioscorea Extracts |
| 02/12/2009 | US20090041802 Immunogenic composition |
| 02/12/2009 | US20090041798 Leishmania sterol 24-c-methyltransferase compositions for the prevention, treatment and diagnosis of leishmaniasis |
| 02/12/2009 | US20090041797 Modified toxins |
| 02/12/2009 | US20090041796 Surface protein of leptospira |
| 02/12/2009 | US20090041795 Synthetic replikin peptides against pathogenic infection of invertebrates in aquaculture |
| 02/12/2009 | US20090041794 Identification of Hla-A2-Presented T-Cell Epitopes Derived from the Oncofoetal Antigen-Immature Laminin Receptor Protein and Uses Thereof |
| 02/12/2009 | US20090041793 Immunostimulatory Compositions and Uses Thereof |
| 02/12/2009 | US20090041790 Methods for treating cardiovascular disease using a soluble CTLA4 molecule |
| 02/12/2009 | US20090041789 Monoclonal Antibodies and Single Chain Antibody Fragments Against Cell-Surface Prostate Specific Membrane Antigen |
| 02/12/2009 | US20090041788 Apo-2L receptor agonist and CPT-11 synergism |
| 02/12/2009 | US20090041787 Chemokine receptor antagonists as therapeutic agents |
| 02/12/2009 | US20090041786 e.g. 5-Fluoro-N4-(3-hydroxyphenyl)-N2-[4-(N-methyl)aminosulfonyl-3-methoxyphenyl]-2,4-pyrimidinediamine; tyrosine (JAK) kinases inhibitor; interleukin and tumor necrosis factor ligand; transplant rejection; T-cell mediated autoimmune disease |
| 02/12/2009 | US20090041785 Use of anti-integrin antibodies for reducing scar tissue formation |
| 02/12/2009 | US20090041784 Compositions and methods relating to glucagon receptor antibodies |
| 02/12/2009 | US20090041783 Anti-platelet membrane glycoprotein vi monoclonal antibody |
| 02/12/2009 | US20090041782 Novel serotype streptococcus mutans and utilization of the same |
| 02/12/2009 | US20090041781 A substantially pure IgE anti-Parvovirus B19 antibody useful for diagnosis and prognosis of parvovirus infected patients by detecting the presence of immunoglobulin E anti-Parvovirus B19 antibodies; antibody-based compositions; viricides |
| 02/12/2009 | US20090041780 Concentrate of Immunoglobulins and F(ab)'2 and/or Fab Fragments Specific of an Arbovirus as a Medicinal Product |
| 02/12/2009 | US20090041779 Aldosterone induced elastin production |
| 02/12/2009 | US20090041778 Methods And Compositions For The Treatment Of Graft Failure |
| 02/12/2009 | US20090041777 G-protein specific immunoglobulin targeting and treatment of viral disorders; Drug screening |
| 02/12/2009 | US20090041776 Production of cancer-specific antibodies in plants |
| 02/12/2009 | US20090041775 Use of CD25 binding molecules in the treatment of inflammatory diseases of the gastro-intestinal tract |
| 02/12/2009 | US20090041774 Haemophilus influenzae type IV pili |
| 02/12/2009 | US20090041773 Methods for diagnosis and treatment of proliferative disorders mediated by cd40 signaling |
| 02/12/2009 | US20090041772 Soluble Forms of Hendra and Nipah Virus G Glycoprotein |
| 02/12/2009 | US20090041771 Immunological methods and compositions for the treatment of Alzheimer's disease |
| 02/12/2009 | US20090041770 Fc VARIANTS WITH ALTERED BINDING TO FcRn |
| 02/12/2009 | US20090041769 Extracellular domain of CTLA4, with (a) methionine at position 27 and ending with aspartic acid at position 150 (b) an alanine at position 26 and ending with aspartic acid at position 150 ; binds CD80 and/or CD86 with greater avidity; lupus, lupus erythematosus, and lupus nephritis |
| 02/12/2009 | US20090041768 Modified Fc molecules |
| 02/12/2009 | US20090041767 Alpha 5 beta 1 integrin antagonist such as volociximab and a tyrosine kinase inhibitor such as sunitinib, sorafenib or bevacizumab; cancer |
| 02/12/2009 | US20090041766 Antibodies for inhibiting blood coagulation and methods of use thereof |
| 02/12/2009 | US20090041765 Modified immunoglobulins for use in prevention and treatment of autoimmune or inflammatory diseases |
| 02/12/2009 | US20090041764 Methods for the treatment of muscular dystrophy associated with dysferlin-deficiency |
| 02/12/2009 | US20090041763 has anti-CTLA-4 antibody; for treating cancer by inducing increase of CD11+CD8+ T cell and IFN- gamma; reduced side effects |
| 02/12/2009 | US20090041762 Methods of treating ankylosing spondylitis using anti-TNF antibodies and peptides of human tumor necrosis factor |
| 02/12/2009 | US20090041761 Method of immunizing animal, composition for immunization, method for producing antibody, method for producing hybridoma and method for producing monoclonal antibody |
| 02/12/2009 | US20090041760 Retroviral immunotherapy |
| 02/12/2009 | US20090041759 Materials and methods for treating ocular-related disorders |
| 02/12/2009 | US20090041758 Modified binding molecules comprising connecting peptides |
| 02/12/2009 | US20090041757 Bone morphogenetic protein antagonist and uses thereof |
| 02/12/2009 | US20090041756 121p1f1: a tissue specific protein highly expressed in various cancers |
| 02/12/2009 | US20090041755 Methods and Compositions For PDGF-D Activation and Inhibition |
| 02/12/2009 | US20090041754 Method for identifying target protein of drug and method for screening therapeutic agent for diabetes using the target protein |
| 02/12/2009 | US20090041753 Cytokine signaling |
| 02/12/2009 | US20090041752 Compositions and methods for the treatment and diagnosis of immune disorders |
| 02/12/2009 | US20090041751 Sepsis Prevention Through Adenosine Receptor Modulation |
| 02/12/2009 | US20090041750 Treatment of spongiform encephalopathy by increased hydrogen peroxide degradation |
| 02/12/2009 | US20090041749 Compositions and methods for the diagnosis and treatment of tumor |
| 02/12/2009 | US20090041746 Combination therapy with IgA1 proteases |
| 02/12/2009 | US20090041726 Tumor therapy with high affinity laminin receptor-target vectors and combinations with chemotherapeutic agents |
| 02/12/2009 | US20090041718 Methods of Modulating Cytokine Activity; Related Reagents |
| 02/12/2009 | US20090041717 High affinity human antibodies to human nerve growth factor |
| 02/12/2009 | US20090041679 Human neutralizing monoclonal antibodies to h5n1 influenza a virus |
| 02/12/2009 | US20090041668 Non-invasive localization of a light-emitting conjugate in a mammal |
| 02/12/2009 | US20090041660 new monoclonal antibodies and binding fragments which recognize and immunoreact with cell surface antigens found on small cell lung cancer (SCLC) cells; antibodies have tumor specificity and are useful for therapy, diagnosis, monitoring, detecting and imaging of SCLC disease |
| 02/12/2009 | US20090041659 Human anti-pseudomonas-aeruginosa antibodies derived from transgenic xenomouse |
| 02/12/2009 | DE102004059357B4 Antikörper, welcher die Interaktion von humanem Thy-1 und dessen Liganden blockiert, sowie dessen Verwendung Antibody that blocks the interaction of human Thy-1 and its ligands, and its use |
| 02/12/2009 | CA2697163A1 Compositions and methods for crystallizing antibodies |
| 02/12/2009 | CA2696303A1 Chlorotoxins as drug carriers |
| 02/12/2009 | CA2695991A1 Immunoliposome inducing apoptosis into cell expressing death domain-containing receptor |
| 02/12/2009 | CA2695894A1 Baculoviral vectors with a dual vertebrate and baculovirus promoter controlling an immunogenic fusion gene |
| 02/12/2009 | CA2695721A1 Immunogenic streptococcus proteins |
| 02/12/2009 | CA2695478A1 Composition and therapeutic anti-tumour vaccine |
| 02/12/2009 | CA2695433A1 Lentiviral gene transfer vectors and their medicinal applications |
| 02/12/2009 | CA2695419A1 Compositions and methods for microbe storage and delivery |
| 02/12/2009 | CA2694434A1 Treatment of prion protein related diseases |
| 02/12/2009 | CA2693464A1 Anti-cd37 antibodies |
| 02/12/2009 | CA2693237A1 Composition and method for treatment of reperfusion injury and tissue damage |
| 02/11/2009 | EP2023143A1 Immunogenic streptococcus proteins |
| 02/11/2009 | EP2022846A1 Method for isolation of stem cell |
| 02/11/2009 | EP2022800A2 Compositions for the therapy and diagnosis of ovarian cancer |
| 02/11/2009 | EP2022507A1 Antibody compositions specific for lgE, lgG4 and lgA epitopes as tools for the design of hypoallergenic molecules for specific immunotherapy |
| 02/11/2009 | EP2022506A2 Method for the treatment of flavivirus infection, molecules and uses thereof |
| 02/11/2009 | EP2021502A1 Novel genes and markers in type 2 diabetes and obesity |
| 02/11/2009 | EP2021490A2 Rpa optimization |
| 02/11/2009 | EP2021483A1 Biomolecule surface display and uses thereof |
| 02/11/2009 | EP2021469A2 Peptide library |
| 02/11/2009 | EP2021372A2 Compositions and methods for modulating immune responses |